Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 3, 2013, Pages 443-449

  Itokawa, Norio ^a   Atsukawa, Masanori ^a   Tsubota, Akihito ^b   Kondo, Chisa ^a   Hashimoto, Satomi ^c   Fukuda, Takeshi ^c   Matsushita, Yoko ^c   Kidokoro, Hideko ^c   Kobayashi, Tamaki ^c   Narahara, Yoshiyuki ^c   Nakatsuka, Katsuhisa ^c   Kanazawa, Hidenori ^c   Iwakiri, Katsuhiko ^a   Sakamoto, Choitsu ^c  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Dynamics; Hepatitis C virus; IFN ; IL28B minor genotype; Ribavirin

Indexed keywords

BETA INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RNA VIRUS; VIRUS LOAD;

EID: 84874389522     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12039     Document Type: Article

References (35)

1. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
2. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol. 2006; 41: 17-27.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-355.
5. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
6. Sakamoto N, Watanabe M. New therapeutic approaches to hepatitis C virus. J. Gastroenterol. 2009; 44: 643-649.
7. Enomoto N, Sakuma I, Asahina Y etal. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996; 334: 77-81.
8. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380.
9. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
10. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
11. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Kurosaki M, Tanaka Y, Nishida N etal. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J. Hepatol. 2011; 54: 439-448.
13. Lin C, Lin K, Luong YP etal. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 2004; 279: 17508-17514.
14. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 2006; 6: 3-16.
15. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob. Agents Chemother. 2006; 50: 1813-1822.
16. Reesink HW, Zeuzem S, Weegink CJ etal. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002.
17. Sarrazin C, Rouzier R, Wagner F etal. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278.
18. Kwo PY, Lawitz EJ, McCone J etal. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
19. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
20. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
21. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009; 360: 1827-1838.
22. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
23. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J. Hepatol. 2012; 56: 78-84.
24. Chayama K, Hayes CN, Abe H etal. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 2011; 204: 84-93.
25. Asahina Y, Izumi N, Uchihara M etal. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34: 377-384.
26. Asahina Y, Izumi N, Uchihara M etal. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J. Hepatol. 2003; 39: 421-427.
27. Hilfenhaus J, Damm H, Hofstaetter T, Mauler R, Ronneberger H, Weinmann E. Pharmacokinetics of human interferon-beta in monkeys. J. Interferon Res. 1981; 1: 427-436.
28. Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Oohashi S, Nishiura S. Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin. Hepatol. Res. 2011; 42: 241-247.
29. Izumi N, Kumada H, Hashimoto N etal. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Dig. Dis. Sci. 2001; 46: 516-523.
30. Okushin H, Morii K, Uesaka K, Yuasa S. Twenty four-week peginterferon plus ribavirin after interferon-beta induction for genotype 1b chronic hepatitis C. World J Hepatol. 2010; 2: 226-232.
31. Matsui K, Iwabuchi S, Shimizu H, Yoshida A, Fujikawa T, Takatsuka K. Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C. Hepatol. Res. 2010; 40: 757-762.
32. Arase Y, Suzuki Y, Suzuki F etal. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Intern. Med. 2011; 50: 2083-2088.
33. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J. Gastroenterol. Hepatol. 2007; 22: 832-836.
34. Yamaji K, Hayashi J, Kawakami Y etal. Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. J. Clin. Gastroenterol. 1998; 26: 193-199.
35. Basu L, Yang CH, Murti A etal. The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon alpha/beta receptor: effects on JAK-STAT activation and receptor down-regulation. Virology 1998; 242: 14-21.